MabVax Therapeutics Holdings, Inc. announced that it has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development of novel Chimeric Antigen Receptor (CAR) T-cell therapeutics using antibody targeting sequences derived from MabVax's fully-human antibodies for pancreatic, small cell lung, and other solid tumor cancers. CAR T-cell therapeutics are unique anti-cancer immunotherapies that genetically modify a patient's own T-cells to recognize an antigen on targeted tumor cells. Under the new agreement, MabVax will provide funding to evaluate the efficacy of multiple CAR T-cell products incorporating several different antibody targeting sequences. The research program will evaluate in xenograft models of pancreatic and small cell lung cancer targeting sequences from MabVax's leading monoclonal antibody clinical development candidate HuMab-5B1. Multiple CAR T-cell constructs have been created and tested in cell based assays demonstrating utility and warranting continued testing in animal models of pancreatic cancer and other CA19-9 expressing tumors.